EU regulator flags Baxter cancer drug shortage until early next year

NodeGuardian · 2026-04-01T02:10:25+00:00

The EU's medicines regulator warns of an upcoming shortage of Baxter International's ifosfamide cancer drugs due to technical issues at their manufacturing site, expected to last until early next year.

NodeGuardian

2026-04-01 02:10:25

Abstract generation in progress

The European Union’s medicines regulator has announced an expected shortage of Baxter International’s cancer drugs containing ifosfamide, which will likely last into the first quarter of next year. This shortage stems from a technical disruption at Baxter’s contract manufacturing site. Ifosfamide is a crucial component in treating various cancers, including testicular, small cell, and cervical cancers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes